Univdatos Whatsapp
Biomarkers Market

Biomarkers Holds Huge Potential in Offering Better Disease Diagnosis to Patients. North America to Witness the Highest Growth.

Biomarkers Market is expected to exceed the market valuation of more than US$ 97 billion by 2027 expanding at a reasonable CAGR of around 13.5% during the forecast period (2021-2027). Biomarkers have been used since decades in clinical medicine. The rise in genomics and other advances in molecular biology, biomarker studies and are entering a completely new era and holding promise for early diagnosis and effective treatment of many diseases. Scientists define biological markers as cellular, biochemical or molecular alterations, which can be measured in biological media like human tissues, cells or fluids. They include biological characteristics, which can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. Various types of biomarkers have been used for generations by epidemiologists, physicians and scientists to study human disease. Application of biomarkers in the diagnosis and management of cardiovascular disease, infections, immunological and genetic disorders and cancer are all well known.

Their use in research has grown from the need to having a more direct measurement to exposures in the causal pathway of disease which is free from recall bias and that can also have the potential of providing information on the absorption and metabolism of the exposures. Biomarkers have also been used by Neuroscientists to assist in the diagnosis and treatment of nervous system disorders and to investigate their cause. Blood, brain, cerebrospinal fluid, nerve, skin, muscle, and urine have been used to gain information about the nervous system in both the healthy and diseased state.

For a detailed analysis of the market drivers in Biomarkers Market browse through – https://univdatos.com/report/biomarkers-market/

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread throughout the world, with significant morbidity and mortality occurring alongside global disruption. The number of cases worldwide continues to increase and is likely to continue to rise further without interventions such as effective contact tracing, social distancing, lockdowns, or vaccination. Common symptoms of the disease include fever, cough, sore throat, headache, fatigue, myalgia, breathlessness, anosmia, and ageusia. Although some biomarkers, such as lymphocyte count, D-dimer, and interleukin (IL)-6, have been reported as risk factors for the severity of COVID-19 infection, most of these biomarkers can be used to distinguish patients with severe disease from normal persons or patients with mild disease. However, estimation of risk factors for COVID-19 disease progression in previous studies is not very robust. Since the risk of COVID-19 is affected by multiple biologically redundant factors, the relationships between these hematological biomarkers may contribute to predicting the progression of COVID-19.

Based on Product, the Biomoarkers Market is segmented into Consumables, Services, and Software. Increase of consumables is because of the increase in the use of kit based products for biomarker testing and the repeated purchase of consumables. Use of biomarkers has become an integral part of both disease detection and treatment. The detection of biomarkers in pre-symptomatic patients leads to the ability to start treatment in early stages of disease, thus drastically improving outcomes.

For a detailed analysis of the Type in the Biomarkers Market browse through – https://univdatos.com/report/biomarkers-market/

Based on Type, the Biomarkers Market is segmented into Safety Biomarkers, Efficacy Biomarkers, Predictive Biomarkers, Surrogate Biomarkers, Pharmacodynamics Biomarkers, Prognostic Biomarkers, and Validation Biomarkers. Efficacy biomarkers indicate clinical outcomes of patients or beneficial effect of a given treatment. For efficacy prediction, general prediction markers for certain therapy strategies (e.g. antihormone treatment in breast cancer) can be differentiated from real companion diagnostic biomarkers (CDx).

Based on Application, the Biomarkers Market is segmented into Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, and Other Applications. Biomarkers are increasingly being used for the diagnosis of diseases like cancer, infectious diseases, cardiovascular disorders and neurological disorders. This is driving the growth of the diagnostics segment in the biomarkers market.

Based on Diseases Indication, the Biomarkers Market is segmented into Cancer, Infectious Diseases, Immune Disorders, Neurological Disorders, Cardiovascular Disorders, and Other Disease Indications. Cancer by Test Type is further segmented into Solid biopsy and Liquid Biopsy. There are many potential applications of biomarkers in oncology, including differential diagnosis, risk assessment, screening, determination of prognosis, prediction of response to treatment and monitoring of progression of disease. Biomarkers play critical roles in all stages of disease, it is important that they undergo rigorous evaluation, including analytical validation, clinical validation and assessment of clinical utility, prior to incorporation into routine clinical care.

Request for Sample of the report browse throughhttps://univdatos.com/get-a-free-sample-form-php/?product_id=14292

Additionally, the report provides detailed initiatives that are being taken in the field of Biomarkers globally. The report provides a detailed analysis of regions including North America (US, Canada, Rest of North America), Europe (Germany, UK, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of Asia-Pacific), Rest of World. North America dominated the market in 2020, with XX% share.

F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, QIAGEN N.V., PerkinElmer, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Enzo Biochem, Inc., Charles River Laboratories International, Inc., and Eurofins Scientific are some of the prominent players operating in the Biomarkers market. Several M&As along with partnerships have been undertaken by these players to make Biomarkers as cost-effective and as widely available as possible.

Biomarkers Market Segmentation

Market Insight, by Product

  • Consumables
  • Services
  • Software

Market Insight, by Type

  • Safety Biomarkers
  • Efficacy Biomarkers
  • Predictive Biomarkers
  • Surrogate Biomarkers
  • Pharmacodynamics Biomarkers
  • Prognostic Biomarkers
  • Validation Biomarkers

Market Insight, by Application

  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Disease Risk Assessment
  • Other Applications

Market Insight, by Disease Indication

  • Cancer
    • Solid biopsy
    • Liquid Biopsy
  • Infectious Diseases
  • Immune Disorders
  • Neurological Disorders
  • Cardiovascular Disorders
  • Other Disease Indications

Market Insight, by Region

  • NORTH AMERICA BIOMARKERS
    • United States
    • Canada
    • Rest of North America
  • EUROPE BIOMARKERS
    • Germany
    • United Kingdom
    • France
    • Spain
    • Italy
    • Rest of Europe
  • ASIA-PACIFIC BIOMARKERS
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • REST OF THE WORLD BIOMARKERS

Top Company Profiles

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • QIAGEN N.V.
  • PerkinElmer, Inc.
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • Enzo Biochem, Inc.
  • Charles River Laboratories International, Inc
  • Eurofins Scientific

Leave A Comment

Select Language